<DOC>
	<DOCNO>NCT00002816</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase III trial compare effectiveness combination chemotherapy treat child relapse acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Relapsed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Improve outcome child first isolated central nervous system ( CNS ) , testicular , ocular relapse acute lymphoblastic lymphoma ( ALL ) , increase knowledge characteristic extramedullary subsequent relapse ALL . II . Quantitate , current molecular biologic technique , occult systemic leukemia case conventional isolated extramedullary relapse , examine relationship assessment subsequent clinical outcome , particularly overt marrow relapse . III . Quantitate occult systemic leukemia subset extramedullary relapse include site ( CNS , testis , eye ) , time relapse ( early late ) , initial risk group , immunophenotype , DNA index karyotype , gender ( CNS eye ) , ethnicity , assess response therapy patient enter companion protocol CCG-B958 . IV . Compare relative sensitivity two quantitative vitro assay occult systemic leukemia ( fluorescence-activated cell sorter/leukemic progenitor cell clonogenic assay vs. polymerase chain reaction-based clonospecific assay ) , correlate assay clinical outcome , assess biologic study leukemic cell ( e.g. , neurotropic potential SCID mouse xenograft model methotrexate sensitivity ) . V. Determine event-free survival ( EFS ) pattern failure child first isolate CNS , testicular , ocular relapse treatment include intensive systemic chemotherapy . VI . Correlate EFS patient CNS ocular relapse sex , patient relapse three site ethnicity . VII . Evaluate impact combine chemotherapy radiotherapy health status survivor two four year extramedullary relapse study entry . OUTLINE : All patient receive induction chemotherapy 5 week : etoposide , ifosfamide/mesna , dexamethasone , vincristine , pegaspargase ( pegaspargase available , E. coli asparaginase may substitute throughout study ) ; dexamethasone , vincristine , pegaspargase ( E. coli asparaginase ) , high-dose methotrexate leucovorin rescue ; triple intrathecal chemotherapy ( TIT ) . Following induction chemotherapy , patient receive two 6-week course intensification therapy intermittent TIT ; course consist dexamethasone , vincristine , high-dose methotrexate/leucovorin , thioguanine , cytarabine , etoposide , pegaspargase ( E. coli asparaginase ) follow dexamethasone , vincristine , high-dose methotrexate/leucovorin , thioguanine , ifosfamide/mesna , idarubicin . Patients receive 2 additional course intensification chemotherapy follow four 12-week course maintenance chemotherapy vincristine methotrexate every 2 week daily oral thioguanine . Total duration therapy 78 week . Patients isolate ocular relapse receive local radiotherapy prior initiation induction chemotherapy ; also CNS leukemia begin TIT radiotherapy . Patients CNS relapse receive craniospinal irradiation first month maintenance therapy , dose field base whether receive TBI whether CNS irradiation previously . Patients testicular relapse receive bilateral testicular irradiation first 3 week intensification therapy . Patients follow every 3 month 3 year , every 6 month 3 year , yearly thereafter , upon relapse , second malignancy , loss follow , death . All patient undergo quality-of-life assessment entry 2 4 year entry . PROJECTED ACCRUAL : Approximately 120 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute lymphoblastic leukemia ( ALL ) isolate extramedullary relapse Relapse occur follow frontline therapy ALL Initial diagnosis 25 % blast L1 L2 morphology No leukemic marrow ( M1 ) conventional assessment Patients B precursor ALL must also enrol study CCGB958 Relapse occur CNS , testis , eye Ocular relapse confirm ophthalmologist cytology iris biopsy Combined CNS ocular relapse eligible Down Syndrome patient eligible No prior bone marrow transplantation first remission No prior toxicity study drug Patient age : Under 21 PATIENT CHARACTERISTICS : See General Eligibility Criteria</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
</DOC>